US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) has taken another gamble outside its traditional cystic fibrosis specialty, this time with the aim of developing curative cell-based treatments for type 1 diabetes.
The Boston-based firm is to pay $950 million to buy privately-held US biotech Semma Therapeutics, the fourth time it has enhanced its pipeline since May, though this deal might be the most ambitious in scope yet given the size of the diabetes market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze